According to Sanxin Medical's announcement, the company raised a total capital of 530 million yuan by issuing convertible corporate bonds to unspecified targets, and the net capital raised after deducting issuance fees was 522 million yuan. The capital was already in place on August 10, 2026. The company and Jiangxi Chengtukang, a wholly-owned second-tier subsidiary, have set up special fund-raising accounts. The company, together with the sponsor Guojin Securities, signed tripartite supervisory agreements with China CITIC Bank Nanchang Branch, ICBC Nanchang Branch, and Huaxia Bank Nanchang Branch, and also signed quadripartite supervisory agreements with Jiangxi Chengtukang, ICBC Nanchang Branch, and Guojin Securities to supervise the storage and use of raised funds.

According to Sanxin Medical's announcement, the company raised a total capital of 530 million yuan by issuing convertible corporate bonds to unspecified targets, and the net capital raised after deducting issuance fees was 522 million yuan. The capital was already in place on August 10, 2026. The company and Jiangxi Chengtukang, a wholly-owned second-tier subsidiary, have set up special fund-raising accounts. The company, together with the sponsor Guojin Securities, signed tripartite supervisory agreements with China CITIC Bank Nanchang Branch, ICBC Nanchang Branch, and Huaxia Bank Nanchang Branch, and also signed quadripartite supervisory agreements with Jiangxi Chengtukang, ICBC Nanchang Branch, and Guojin Securities to supervise the storage and use of raised funds.